# Remedy Plan Therapeutics

Source: https://onco.cc/companies/remedy-plan-therapeutics/  
OnCo record `remedy-plan-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Remedy Plan Therapeutics develops RPT1G, a medicine that blocks NAMPT, an enzyme cancer cells rely on for energy. It is in an early trial in acute myeloid leukaemia and high-risk myelodysplastic syndromes.

## Summary

Remedy Plan Therapeutics is a clinical-stage biotechnology company whose lead, RPT1G, is described as a first-in-class hyperbolic inhibitor of NAMPT, an enzyme the company says is dysregulated in many diseases including cancer. After a phase 1 study in healthy adults (NCT06667765) and FDA IND clearance announced in November 2025, RPT1G entered a multi-centre, open-label 3+3 dose-escalation trial in relapsed or refractory acute myeloid leukaemia and high-risk myelodysplastic syndromes (NCT07107126); in September 2026 the company reported that cohort 1 had completed a full 28-day cycle and cohort 2 had begun enrolling. The same release, datelined Gaithersburg, Maryland, reported a Series A extension of about USD 30 million with participation from Schooner Capital and mainly existing investors. Its first registered cancer trial, NCT07107126, was posted on ClinicalTrials.gov in August 2025; its first registry study, the healthy volunteer trial NCT06667765, was posted in October 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Remedy Plan, Inc.
- HQ: Gaithersburg, MD
- Type: biotech
- Website: https://www.remedyplan.com/

## Notes

- Founding year not stated on the pages read; headquarters taken from the Gaithersburg, MD dateline.
- The technology id metabolic-therapy is used because NAMPT inhibition depletes the NAD supply of cancer cells.
- Company website and September 2026 release read on 29 October 2026.

## Sources

- Official website: https://www.remedyplan.com/
- September 2026 milestones and financing release: https://www.remedyplan.com/press-releases-1/remedy-plan-therapeutics-announces-multiple-development-and-corporate-milestones-as-first-in-class-hyperbolic-nampt-inhibitor-rpt1g-advances-in-phase-1-dose-escalation-trial-in-amlmds
- ClinicalTrials.gov: phase 1 trial of RPT1G in AML and MDS (NCT07107126): https://clinicaltrials.gov/study/NCT07107126
- ClinicalTrials.gov: phase 1 healthy volunteer study of RPT1G (NCT06667765): https://clinicaltrials.gov/study/NCT06667765

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Higher-risk myelodysplastic syndromes](https://onco.cc/cancers/mds-higher-risk/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Metabolic therapy: starving the tumour of a nutrient](https://onco.cc/technologies/metabolic-therapy/)

---
JSON: https://onco.cc/api/v1/entities/remedy-plan-therapeutics.json